Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Advanced Solid Tumors 10Solid Tumors 8Solid Tumor 8Unspecified Adult Solid Tumor, Protocol Specific 7Mesothelioma 6Mesothelioma, Malignant 3Advanced Solid Tumor 3Advanced/Metastatic Solid Tumors 2Advanced Solid Tumour 2Uterine Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Tumor, Adult 1Select Advanced Solid Tumors 1Refractory Solid Tumors in Children 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Malignant Solid Tumour 1MSI-H Advanced Colorectal Cancer 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Cervical Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced HCC 1

Interventions

Cisplatin 6Pemetrexed 5cediranib 3Chemotherapy, Adjuvant 3Radiotherapy 2Neoadjuvant Therapy 2Gemcitabine 2vatalanib 1rilotumumab 1pembrolizumab 1belinostat 1Watchful Waiting 1Vinorelbine 1Talc 1Sorafenib 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pharmacogenomic Testing 1Methotrexate 1Immunoenzyme Techniques 1Gefitinib 1Erlotinib Hydrochloride 1Dihematoporphyrin Ether 1Dasatinib 1Capecitabine 1Bevacizumab 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumor, Pleural × Bevacizumab × Other solid neoplasm × Clear all
NCT00027703 2014-02-11

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

National Cancer Institute (NCI)

Phase 2 Completed
106 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡